Full Press Release Details
Protalix BioTherapeutics to Present at
UBS Global Life Sciences Conference
CARMIEL, Israel September 19, 2007 Protalix BioTherapeutics, Inc. (Amex: PLX), today
announced that Dr. David Aviezer, its President and Chief Executive Officer, will present at the
UBS Global Life Sciences Conference at the Grand Hyatt New York on Monday, September 24, 2007, at
The Company s presentation can be accessed live via webcast at
http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070924. Following the live
presentation, the archived webcast will be available for a period of 30 days.
About Protalix BioTherapeutics, Inc.
Protalix is a clinical stage biopharmaceutical company. Its goal is to become a fully
integrated biopharmaceutical company focused on focused on the development and commercialization of
proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell
based protein expression system, ProCellExTM. ProCellEx presents a proprietary method
for the expression of recombinant proteins that Protalix believes is safe and scalable and will
allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins.
Protalix has initiated enrollment and treatment of patients in its pivotal phase III clinical trial
of its lead product candidate, prGCD, for enzyme replacement therapy of Gaucher disease, a
lysosomal storage disorder in humans. The final design of the pivotal phase III clinical trial is
based on an agreement reached by Protalix with the United States Food and Drug Administration,
through its Special Protocol Assessment (SPA). Protalix is also advancing additional recombinant
biopharmaceutical drug development programs.
Safe Harbor Statement:
To the extent that statements in this press release are not strictly historical, all such
statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known
and unknown risks and uncertainties that may cause actual future experience and results to differ
materially from the statements made. These statements are based on our current beliefs and
expectations as to such future outcomes. Drug discovery and development involve a high degree of
risk. Factors that might cause such a material difference include, among others, uncertainties
related to the ability to attract and retain partners for our technologies and products under
development, the identification of lead compounds, the successful preclinical development of our
products, the completion of clinical trials, the review process of the FDA, foreign regulatory
bodies and other governmental regulation, and other factors described in our filings with the
Securities and Exchange Commission. The statements are valid only as of the date hereof and we
disclaim any obligation to update this information.
For additional information, contact Protalix BioTherapeutics at:
AMEX IR Alliance for Protalix Biotherapeutics
Lee Roth / David Burke